Exact Mass: 882.4146

Exact Mass Matches: 882.4146

Found 31 metabolites which its exact mass value is equals to given mass value 882.4146, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Velpatasvir

methyl N-[2-(2-{4-[6-(1-{2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl)-21-oxa-5,7-diazapentacyclo[11.8.0.0^{3,11}.0^{4,8}.0^{14,19}]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-3H-imidazol-2-yl}-4-(methoxymethyl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl]carbamate

C49H54N8O8 (882.4064)


   

PGP(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PGP(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C41H72O16P2 (882.4295)


PGP(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-2-[(12-methyltetradecanoyl)oxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C41H72O16P2 (882.4295)


PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2S)-2-hydroxy-3-({hydroxy[(2R)-3-[(13-methyltetradecanoyl)oxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C41H72O16P2 (882.4295)


PGP(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-2-[(13-methyltetradecanoyl)oxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C41H72O16P2 (882.4295)


PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

Spirostane -2H, + 1O, O-Hex-dHex, C6H9O4

Spirostane -2H, + 1O, O-Hex-dHex, C6H9O4

C45H70O17 (882.4613)


Annotation level-3

   
   

dracaenoside I

dracaenoside I

C45H70O17 (882.4613)


   

Docusate Calcium

calcium 1,4-bis(2-ethylhexyl) bis(2-sulphosuccinate)

C40H74CaO14S2 (882.4146)


C78276 - Agent Affecting Digestive System or Metabolism > C29697 - Laxative > C29699 - Stool Softener D013501 - Surface-Active Agents

   

Trillfurostanoside F

26-O-beta-D-glucopyranosyl-(25R)-furost-5,16(17),20(22)-trien-3beta,26-diol-3-O-alpha-l-rhamnopyranosyl-(1-2)-beta-D-glucopyranoside

C45H70O17 (882.4613)


   

1,1,3,3-tetrabutyl-1,3-bis[(1-oxododecyl)oxy]distannoxane

1,1,3,3-tetrabutyl-1,3-bis[(1-oxododecyl)oxy]distannoxane

C40H82O5Sn2 (882.4206)


   

velpatasvir

velpatasvir

C49H54N8O8 (882.4064)


D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

zinc isodecyl phosphorodithioate

zinc isodecyl phosphorodithioate

C40H84O4P2S4Zn (882.4019)


   

[(E,5S,9S,10S)-11-[(10S,16S,20S,21R,22S,24E)-16-hydroxy-22-methoxy-10,21-dimethyl-12,18-dioxo-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.12,5.16,9]hentriaconta-1(28),2(31),4,6(30),8,24,26(29)-heptaen-20-yl]-1-[hydroxymethyl(methyl)amino]-10-methoxy-3,5,9-trimethyl-6-oxoundec-1-en-4-yl] acetate

[(E,5S,9S,10S)-11-[(10S,16S,20S,21R,22S,24E)-16-hydroxy-22-methoxy-10,21-dimethyl-12,18-dioxo-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.12,5.16,9]hentriaconta-1(28),2(31),4,6(30),8,24,26(29)-heptaen-20-yl]-1-[hydroxymethyl(methyl)amino]-10-methoxy-3,5,9-trimethyl-6-oxoundec-1-en-4-yl] acetate

C46H66N4O13 (882.4626)


   

Spirostane-2H, + 1O, O-Hex-dHex, C6H9O4

Spirostane-2H, + 1O, O-Hex-dHex, C6H9O4

C45H70O17 (882.4613)


   

PGP(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PGP(a-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C41H72O16P2 (882.4295)


   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0)

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/a-15:0)

C41H72O16P2 (882.4295)


   

PGP(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PGP(i-15:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C41H72O16P2 (882.4295)


   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0)

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-15:0)

C41H72O16P2 (882.4295)


   

Brachystemin H

Brachystemin H

C45H58N10O9 (882.4388)


A natural product found in Brachystemma calycinum.

   
   

2-[({3-benzyl-2,5,8,14-tetrahydroxy-10-methyl-6-[(methyl-c-hydroxycarbonimidoyl)methyl]-11-oxo-9-(2-phenylethyl)-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,7,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-3-phenylpropanoic acid

2-[({3-benzyl-2,5,8,14-tetrahydroxy-10-methyl-6-[(methyl-c-hydroxycarbonimidoyl)methyl]-11-oxo-9-(2-phenylethyl)-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,7,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-3-phenylpropanoic acid

C47H62N8O9 (882.464)


   

(3s)-5-[(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

(3s)-5-[(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

C45H70O17 (882.4613)


   

2-{[3-hydroxy-2-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-6-{7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-eneoxy}oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{[3-hydroxy-2-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-6-{7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-eneoxy}oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C45H70O17 (882.4613)


   

(3s)-5-[(1's,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

(3s)-5-[(1's,2r,2's,4's,5s,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

C45H70O17 (882.4613)


   

5-(16'-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy)-3-hydroxy-3-methyl-5-oxopentanoic acid

5-(16'-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy)-3-hydroxy-3-methyl-5-oxopentanoic acid

C45H70O17 (882.4613)


   

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-3-hydroxy-2-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-6-[(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,16's)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-eneoxy]oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-3-hydroxy-2-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-6-[(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,16's)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-eneoxy]oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C45H70O17 (882.4613)


   

5-[(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

5-[(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

C45H70O17 (882.4613)


   

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4s,5s)-5-hydroxy-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-{[(2s,3r,4s,5s)-5-hydroxy-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-9-(hydroxymethyl)-6a,6b,9,12a-tetramethyl-2-methylidene-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C45H70O17 (882.4613)


   

(3s)-5-[(1's,2r,2's,4's,5r,7's,8'r,9's,12'r,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

(3s)-5-[(1's,2r,2's,4's,5r,7's,8'r,9's,12'r,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-7',9',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-5-ylmethoxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

C45H70O17 (882.4613)